Drugs / XmAb541
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07593092 | Jun 2026 → Dec 2028 expected | ovarian cancer | Xencor, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06276491 | Apr 2024 → Dec 2027 expected | endometrial cancer, ovarian cancer, ovarian germ cell tumor, testicular germ cell tumor | Xencor, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb541 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07593092 ↗ |
| Modality | Monoclonal antibody | “Monoclonal bispecific antibody” NCT06276491 ↗ |
| Route | Intravenous | “Intravenous or Subcutaneous administration” NCT06276491 ↗ |
| Route | Subcutaneous | “Intravenous or Subcutaneous administration” NCT06276491 ↗ |